These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 1972362

  • 21. [Independence of the delayed hypersensitivity response from protection against Leishmania mexicana pifanoi].
    Pérez HA, De la Rora M.
    Acta Cient Venez; 1986; 37(5):542-6. PubMed ID: 2966535
    [No Abstract] [Full Text] [Related]

  • 22. Variants with reduced virulence derived from Leishmania major after mutagen treatment.
    Marchand M, Daoud S, Titus RG, Louis J, Boon T.
    Parasite Immunol; 1987 Jan; 9(1):81-92. PubMed ID: 3562060
    [Abstract] [Full Text] [Related]

  • 23. Leishmania major: analysis of lymphocyte and macrophage cellular phenotypes during infection of susceptible and resistant mice.
    Heinzel FP, Sadick MD, Locksley RM.
    Exp Parasitol; 1988 Apr; 65(2):258-68. PubMed ID: 3127233
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Prophylactic immunization against experimental leishmaniasis. V. Mechanism of the anti-protective blocking effect induced by subcutaneous immunization against Leishmania major infection.
    Liew FY, Singleton A, Cillari E, Howard JG.
    J Immunol; 1985 Sep; 135(3):2102-7. PubMed ID: 3160786
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens.
    Scott P, Natovitz P, Coffman RL, Pearce E, Sher A.
    J Exp Med; 1988 Nov 01; 168(5):1675-84. PubMed ID: 2903212
    [Abstract] [Full Text] [Related]

  • 29. L3T4+ T cells promoting susceptibility to murine cutaneous leishmaniasis express the surface marker Ly-24 (Pgp-1).
    Moll H, Scollay R.
    Eur J Immunol; 1989 Feb 01; 19(2):307-14. PubMed ID: 2467816
    [Abstract] [Full Text] [Related]

  • 30. Examination of variables in the vaccination of mice against cutaneous leishmaniasis using living avirulent cloned lines and killed promastigotes of Leishmania major.
    Mitchell GF, Handman E, Spithill TW.
    Int J Parasitol; 1985 Dec 01; 15(6):677-84. PubMed ID: 4093239
    [No Abstract] [Full Text] [Related]

  • 31. Immunization of susceptible BALB/c mice against Leishmania braziliensis. I. Resistance induced using as immunogen adherent or nonadherent cells from infected mice.
    Gorczynski RM.
    Cell Immunol; 1985 Aug 01; 94(1):1-10. PubMed ID: 3160485
    [Abstract] [Full Text] [Related]

  • 32. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice.
    Titus RG, Marchand M, Boon T, Louis JA.
    Parasite Immunol; 1985 Sep 01; 7(5):545-55. PubMed ID: 3877902
    [Abstract] [Full Text] [Related]

  • 33. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
    Hugentobler F, Di Roberto RB, Gillard J, Cousineau B.
    Vaccine; 2012 Aug 24; 30(39):5726-32. PubMed ID: 22814408
    [Abstract] [Full Text] [Related]

  • 34. Leishmania major: a clone with low virulence for BALB/c mice elicits a Th1 type response and protects against infection with a highly virulent clone.
    Li J, Nolan TJ, Farrell JP.
    Exp Parasitol; 1997 Sep 24; 87(1):47-57. PubMed ID: 9287957
    [Abstract] [Full Text] [Related]

  • 35. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism.
    Sadick MD, Heinzel FP, Holaday BJ, Pu RT, Dawkins RS, Locksley RM.
    J Exp Med; 1990 Jan 01; 171(1):115-27. PubMed ID: 2104918
    [Abstract] [Full Text] [Related]

  • 36. IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis.
    Scott P.
    J Immunol; 1991 Nov 01; 147(9):3149-55. PubMed ID: 1833466
    [Abstract] [Full Text] [Related]

  • 37. In vitro assessment of anti-Leishmania immunity of man acquired with a vaccine.
    Vouldoukis I, Ogunkolade BW, Frommel D, Alier N, Monjour L.
    Experientia; 1988 Jan 15; 44(1):56-7. PubMed ID: 3350121
    [Abstract] [Full Text] [Related]

  • 38. Characterization of Leishmania major antigen-liposomes that protect BALB/c mice against cutaneous leishmaniasis.
    Kahl LP, Lelchuk R, Scott CA, Beesley J.
    Infect Immun; 1990 Oct 15; 58(10):3233-41. PubMed ID: 2401562
    [Abstract] [Full Text] [Related]

  • 39. Immunological regulation of experimental cutaneous leishmaniasis. III. Nature and significance of specific suppression of cell-mediated immunity in mice highly susceptible to Leishmania tropica.
    Howard JG, Hale C, Liew FY.
    J Exp Med; 1980 Sep 01; 152(3):594-607. PubMed ID: 6447751
    [Abstract] [Full Text] [Related]

  • 40. Leishmania tropica infection, in comparison to Leishmania major, induces lower delayed type hypersensitivity in BALB/c mice.
    Mahmoudzadeh-Niknam H, Kiaei SS, Iravani D.
    Korean J Parasitol; 2007 Jun 01; 45(2):103-9. PubMed ID: 17570972
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.